641 / 1498
Follow up:
Local progression and Late toxicity
every 6 months for 2 years, annually thereafter
ELIGIBLE PATIENT
Histologically proven follicular or marginal zone NHL
receiving radiotherapy for definitive treatment of stage I/II
disease or for palliation by virtue of bulk or anatomical site
12 weeks:
Tumour Response and Late toxicity
RANDOMISATION
Stratified by diagnosis (FL/MZL) and treatment intent (palliative/curative)
4 weeks:
Local progression and Acute toxicity
ARM A CONTROL
24Gy
in 12 fractions
ARM B EXPERIMENTAL
4Gy
in 2 fractions
18